Nutriband Inc. (FRA:9WV)

Market Cap	49.01M +7.1%
Revenue (ttm)	1.98M +12.7%
Net Income	-29.99M
EPS	-2.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	3.500
Previous Close	3.620
Day's Range	3.500 - 3.500
52-Week Range	3.320 - 9.850
Beta	n/a
RSI	45.47
Earnings Date	Apr 28, 2026

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agre...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Country: United States
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9WV

Financial Performance

In fiscal year 2025, Nutriband's revenue was $2.14 million, an increase of 2.60% compared to the previous year's $2.09 million. Losses were -$10.48 million, 91.1% more than in 2024.

Financial numbers in USD